A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Qing Zhu(Altimmune (United States)), JoAnn Suzich, Patricia C. Ryan(Altimmune (United States)), Andy Q. Yuan, Catherine Svabek(Altimmune (United States)), Brian Moldt(Altimmune (United States)), Daniel Wrapp(Duke University), Jing Zhang(Beihang University), Anis A. Khan(Altimmune (United States)), Nancy D. Ulbrandt(Altimmune (United States)), Kimberly E. Cook, Josephine M. McAuliffe(Altimmune (United States)), Nicole L. Kallewaard(Altimmune (United States)), Nita Patel(Novavax (United States)), Jason S. McLellan(The University of Texas at Austin), Bettina Richter(Altimmune (United States)), Susan Palaszynski(Altimmune (United States))
Cited by 361
Related Papers
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
|Science|2020|9.8k
Site-specific glycan analysis of the SARS-CoV-2 spike
|Science|2020|1.7k
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
|Science|2020|1.4k
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
|Proceedings of the National Academy of Sciences|2017|1.2k